Exclusive Wu Xiaobin, Vice President of the China Pharmaceutical Promotion Association: China's innovative drugs should benefit countries along the Belt and Road

China has always regarded medical and health services as an important part of exchanges and cooperation between countries, and medical and health services as a popular project, which plays an important role in enhancing mutual trust and cooperation between China and the countries along the Belt and Road.
Recently, China Belt and Road Network invited Wu Xiaobin, vice president of the China Pharmaceutical Promotion Association and vice president of the China Chemical Pharmaceutical Industry Association, to analyze the current situation of China's biopharmaceutical industry and the development of China's pharmaceutical industry along the Belt and Road.
recent years, Thanks to the support of various national policies and measures, China's pharmaceutical industry, especially the biopharmaceutical industry, has a good momentum of innovation, and private capital has accelerated its influx into the field of pharmaceutical innovation.
data show that China's pharmaceutical market grew at an annualized rate of 8.1% from 2014 to 2018, from 1.1 trillion yuan to 1.5 trillion yuan, reaching 1.75 trillion yuan in 2020.
China's Belt and Road Network: What has been the development of biopharmaceuticals and innovative drugs in China in recent years? Wu Xiaobin: Over the past few decades of China's reform and opening-up, foreign companies such as Pfizer and Baier have entered the Chinese market, bringing about changes and upgrading in China's medical and pharmaceutical industries and promoting exchanges in the international medical community.
the past few years, there have been many changes in national policies, such as the State Drug Administration to vigorously develop drug reform, China's biopharmaceutical industry to bring spring.
with policy support, while absorbing, learning international advanced technology and innovation, China's pharmaceutical industry has developed very rapidly in the past five or six years.
believe that in another five to ten years, a significant proportion of breakthrough innovative drugs must have been developed in China.
-made new crown vaccine on display at the Beijing Service Fair in September.
(Source: China Belt and Road Network) Medical cooperation to promote the "Belt and Road" people's hearts and hearts with the "Belt and Road" construction of the deepening, China and countries along the road medical exchanges and cooperation continued to strengthen, China's modern medical technology, traditional Chinese medicine and other accelerated to countries along the line.
present, the "Belt and Road" along the countries and regions, health care industry demand is strong, to promote the development of health care cooperation, the construction of people's hearts project, will be particularly important.
China Belt and Road Network: What do you think the development of China's pharmaceutical industry can do to promote the "Health Silk Road"? Wu Xiaobin: When it comes to internationalization in the past, it means that Chinese manufacturing goes to Europe and the United States, and we've done it.
Now when it comes to the internationalization of medicine, the countries along the Belt and Road cannot be ignored, and from the point of view of GDP and economic development, there is still a certain gap between the countries along the Belt and Road compared with the developed countries.
in China, patients who were treated for cancer or rare diseases relied heavily on innovative drugs from large international companies, which were expensive and delayed because they could not afford them for long periods of time.
in the countries along the Belt and Road today face similar dilemmas to those in China in the past.
past few years, China has begun to innovate the independent development of drugs and is beginning to bear fruit, in terms of price, domestic innovative drugs are the international large companies of innovative drugs a quarter to a third.
medicine has no borders, domestic innovative drugs can benefit the Chinese people, I believe it will also benefit the "Belt and Road" along the people of the countries.
affordability, home-grown innovative drugs have made it possible to treat cancer and rare diseases in more countries along the route.
years, China's series of "Bright Walk" activities in countries along the Belt and Road has brought light to many poor local patients and become the "People's Heart Project" on the Belt and Road.
(Source: Xinhua) -- Opportunities and Challenges for China's Pharmaceutical Industry in the Post-Epidemic Period, November 3, 2020 China Biotechnology Innovation Conference was held in Suzhou Industrial Park.
Zhong Nanshan, a member of the Chinese Academy of Engineering, said in a video message that in recent years, China's biotechnology sector has experienced rapid innovation, continuous improvement of innovation system construction, rapid improvement of research and development capabilities and levels, and increasing role in supporting economic and social development.
in the course of the war, biotechnology in the prevention and treatment of new crown pneumonia plays an important role.
at a regular press conference at the Chinese Foreign Ministry on November 17, Foreign Ministry spokesman Zhao Lijian pointed out that China's vaccine companies are making every effort to promote vaccine research and development, and that China has several vaccines in Phase III clinical trials.
Chinese government has also been actively supporting Chinese companies to cooperate with other countries in vaccine research and development.
China's Belt and Road Network: this year's outbreak came very suddenly, the continuous impact of a long time, the impact of large-scale.
environment, what are the opportunities and challenges of China's pharmaceutical industry? Wu Xiaobin: Let's start with the opportunity, China's biopharmaceutical industry has developed rapidly in recent years and has played a very important role in this outbreak.
think that China's rapid success in fighting the epidemic is due to two points.
first, the institutional advantages of our country.
, China's high level of biotechnology, the first time to make kits, so that the epidemic prevention and control has a direction and objectives.
vaccines, there are currently 10 vaccines in Phase III clinical trials around the world, four of which were developed in China, and, unsurprisingly, China will soon be able to successfully launch the vaccine.
treatment, whether it is the antibody, or other chemical drugs, our country's research and development speed, quality, variety, are among the best in the world, this gives the chinese people a lot of confidence and strength.
we Chinese used to say that there is food in hand, the heart does not panic, that is the truth.
challenge, from the current international situation, there are many countries pursue unilateralism, so how to fully establish China's biopharmaceutical core competitiveness is very important.
There is still a certain distance between China's innovative drugs in various fields and the world's most advanced innovative drugs, but this distance, I believe that with the support of national policies, China's innovative pharmaceutical industry can quickly catch up.
source, China Belt and Road Network author Wang Yu, edited Cao Jianing's supervision of Li Shen's copyright in this article is owned by the "China Belt and Road Network"